Positive: DSMB recommends Vaxart's COVID-19 Phase 2b trial to proceed without modifications.

From GlobeNewswire: 2025-01-13 19:55:00

An independent Data Safety Monitoring Board (DSMB) recommends Vaxart’s COVID-19 Phase 2b trial to proceed without modifications based on initial safety assessment of 400 participants. The company plans to enroll 10,000 participants pending FDA and BARDA approval. The trial will compare Vaxart’s oral pill vaccine candidate to an mRNA COVID-19 injectable vaccine. Funding for the project was received under Project NextGen, valued at up to $460.7 million. Vaxart is a pioneer of oral vaccines and the first U.S. company to complete a Phase 2 trial for an oral COVID-19 vaccine. For more information, contact Vaxart Media and Investor Relations at [email protected] or (646) 871-8481.



Read more at GlobeNewswire: Vaxart Announces Favorable DSMB Review of Sentinel Cohort